Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients

Multiple Sclerosis

Volumn 14, Issue 8, 2008, Pages 1056-1060

  Hirotani, M ^a   Maita, C ^b   Niino, Masaaki ^a   Iguchi Ariga, S M ^b   Hamada, S ^c   Ariga, H ^b   Sasaki, H ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Hokuyukai Neurology Hospital   (Japan)

Author keywords

Cerebrospinal fluids; DJ 1; Multiple sclerosis; Multiple sclerosis severity score; Neurodegenerative process; Oxidative stress

Indexed keywords

DJ 1 PROTEIN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY SEVERITY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCORING SYSTEM; BLOOD; CEREBROSPINAL FLUID; DISABLED PERSON; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITALIZATION; PATHOPHYSIOLOGY; REFERENCE VALUE;

ADULT; DISABLED PERSONS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MULTIPLE SCLEROSIS; ONCOGENE PROTEINS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX;

EID: 58149340184     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508093616     Document Type: Article

References (34)

1. Kim, RH, Smith, PD, Aleyasin, H, et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 2005; 102: 5215-5220.
2. Rovaris, M, Confavreux, C, Furlan, R, Kappos, L, Comi, G, Filippi, M. Secondary progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurol 2006; 5: 343-354.
3. Nagakubo, D, Taira, T, Kitaura, H, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997; 231: 509-513.
4. Bonifati, V, Oostra, BA, Heutink, P. Linking DJ-1 to neurodegeneration offers novel insights for understanding the pathogenesis of Parkinson's disease. J Mol Med 2004; 82: 163-174.
5. Taira, T, Takahashi, K, Kitagawa, R, Iguchi-Ariga, SM, Ariga, H. Molecular cloning of human and mouse DJ-1 genes and identification of Sp1-dependent activation of the human DJ-1 promoter. Gene 2001; 263: 285-292.
6. Bader, V, Ran Zhu, X, Lübbert, H, Stichel, CC. Expression of DJ-1 in the adult mouse CNS. Brain Res 2005; 1041: 102-111.
7. Waragai, M, Wei, J, Fujita, M, et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006; 345: 967-972.
8. Bandopadhyay, R, Kingsbury, AE, Cookson, MR, et al. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2004; 127: 420-430.
9. Rizzu, P, Hinkle, DA, Zhukareva, V, et al. DJ-1 colocalizes with tau inclusions: A link between Parkinsonism and dementia. Ann Neurol 2004; 55: 113-118.
10. Saha, RN, Pahanm, K. Tumor necrosis factor-alpha at the crossroad of neuronal life and death during HIVassociated dementia: A review. J Neurochem 2003; 86: 1057-1071.
11. Lev, N, Ickowicz, D, Barhum, Y, Blondheim, N, Melamed, E, Offen, D. Experimental encephalomyelitis induces changes in DJ-1: Implications for oxidative stress in multiple sclerosis. Antioxid Redox Signal 2006; 8: 1987-1995.
12. Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
13. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
14. Roxburgh, RHSR, Seaman, SR, Masterman, T, et al. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
15. McShane, LM, Altman, DG, Sauerbrei, W, Taube, SE, Gion, M, Clark, GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005; 2: 416-422.
16. Maita, C, Tsuji, S, Yabe, I, et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 2007; 431: 86-89.
17. Gonsette, RE. Oxidative stress and excitotoxicity: A therapeutic issue in multiple sclerosis. Mult Scler 2007; 14: 22-34.
18. Block, ML, Hong, JS. Microglia and inflammationmediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
19. Langemann, H, Kabiersch, A, Newcombe, J. Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 1992; 32: 248-252.
20. Le Vine, SM, Wetzel, DL. Chemical analysis of multiple sclerosis lesions by FT-IR microspectroscopy. Free Radic Biol Med 1998; 25: 33-41.
21. MacMicking, JD, Willenborg, DO, Weidemann, MJ, Rockett, KA, Cowden, WB. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: Enhancement by the soluble products of encephalitogenic T cells. J Exp Med 1992; 176: 303-307.
22. Naidoo, R, Knapp, ML. Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 1992; 38: 2449-2454.
23. Le Vine, SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 1992; 39: 271-274.
24. Liu, JS, Zhao, ML, Brosnan, CF, Lee, SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057-2066.
25. Lu, F, Selak, M, O'Connor, J, et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000; 177: 95-103.
26. Qi, X, Lewin, AS, Sun, L, Hauswirth, WW, Guy, J. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 2006; 281: 31950-31962.
27. Andrews, HE, Nichols, PP, Bates, D, Turnbull, DM. Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis. Med Hypotheses 2005; 64: 669-677.
28. Kalman, B, Leist, TP. A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular Med 2003; 3: 147-158.
29. Mitsumoto, A, Nakagawa, Y, Takeuchi, A, Okawa, K, Iwamatsu, A, Takanezawa, Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 2001; 35: 301-310.
30. Canet-Aviles, RM, Wilson, MA, Miller, DW, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004; 101: 9103-9108.
31. Li, HM, Niki, T, Taira, T, Iguchi-Ariga, SM, Ariga, H. Association of DJ-1 with chaperones and enhanced association and colocalization with mitochondrial Hsp70 by oxidative stress. Free Radic Res 2005; 39: 1091-1099.
32. Taira, T, Saito, Y, Niki, T, Iguchi-Ariga, SM, Takahashi, K, Ariga, H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5: 213-218.
33. Kinumi, T, Kimata, J, Taira, T, Ariga, H, Niki, E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004; 317: 722-728.
34. Kim, RH, Peters, M, Jang, Y, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005; 7: 263-273.